



5-9-05

Ifw
\$

CKET NO.: AM101201 US/WYNC-0325

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Deborah A. Evrard, et al.

Confirmation No.: 4846

Application No.: 10/659,537

Group Art Unit: 1624

Filing Date: September 10, 2003

Examiner: Emily B. Bernhardt

**For: ANTIDPRESSANT ARYLPIPERAZINE DERIVATIVES OF
HETEROCYCLE-FUSED BENZODIOXANS**

**EXPRESS MAIL LABEL NO: EV 614725845 US
DATE OF DEPOSIT: May 6, 2005**

EV614725845US

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 CFR § 1.56 and in accordance with 37 CFR §§ 1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 CFR § 1.56(b).

- ☐ In accordance with § 1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in § 1.491, before the mailing date of a first Office Action on the merits of the above-identified application, or

before the mailing date of a first Office Action after the filing of request for continued examination under § 1.114, no additional fee is required.

- ☒ In accordance with § 1.97(c), this Information Disclosure Statement is being filed after the period set forth in § 1.97(b) above but before the mailing date of either a Final Action under § 1.116 or a Notice of Allowance under § 1.311, or before an action that otherwise closes prosecution in the application, therefore:

☐ Certification in Accordance with § 1.97(e) is attached; or

☒ The fee of \$180.00 as set forth in § 1.17(p) is attached.

- ☐ In accordance with § 1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under § 1.113 or a Notice of Allowance under § 1.311 but before, or simultaneously with, the payment of the Issue Fee, therefore included are: Certification in Accordance with § 1.97(e); and the submission fee of \$180.00 as set forth in § 1.17(p).

- ☒ Copies of reference numbers 23-29 listed on the attached Form PTO-1449 are enclosed herewith.

- ☐ Copies of reference numbers - on the attached Form PTO 1449 are not required to be submitted pursuant to 37 CFR § 1.98(a)(2)(i).

- ☐ Copies of references - are not being submitted because they were previously cited by or submitted to the U.S. Patent and Trademark Office in patent application number , filed for which a claim for priority under 35 U.S.C. § 120 has been made in the instant application.


There are no listed references which are not in the English language.

DOCKET NO.: AM101201 US/WYNC-0325- 3 -

PATENT

Please charge any deficiency or credit any overpayment to Deposit Account No. 23-3050. This form is submitted in duplicate.

Date: May 6, 2005


Wendy A. Choi
Registration No. 36,697

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
Telephone: (215) 568-3100
Facsimile: (215) 568-3439

© 2005 WW



Sheet 1 of 1

Form PTO-1449 Modified List of Patent and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce Patent and Trademark Office	Docket No. AM101201 US/ WYNC-0325		Application No. 10/659,537	
	Applicant Deborah A. Evrard, et al.			
	Filing Date September 10, 2003		Group 1624	
	Confirmation No. 4846			
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
	23	Bundgaard, H. (ed.), <i>Design of Prodrugs</i> , Elsevier (1985), Ch. 1 (pp. 1-92), Ch. 4 (pp. 157-176), Ch. 5 (pp. 177-198), and Ch. 6 (pp. 199-241).		
	24	Bundgaard, H. et al., "Glycolamide Esters as Biolabile Prodrugs of Carboxylic Acid Agents: Synthesis, Stability, Bioconversion, and Physicochemical Properties," <i>J. of Pharmaceutical Sciences</i> , April 1988, 77(4):285-298		
	25	Eliel, E. L., <i>Stereochemistry of Carbon Compounds</i> , McGraw Hill, NY (1962) Ch. 4, pp. 46-87		
	26	Higuchi and Stella (eds.), <i>Prodrugs as Novel Drug Delivery Systems</i> , American Chemical Society (1975), pp. 1-115 and 196-223		
	27	Jacques, J. et al., <i>Enantiomers, Racemates and Resolutions</i> , Wiley Interscience, NY (1981) pp. 251-434		
	28	<i>Remington's Pharmaceutical Sciences</i> , 17 th Ed., Gennaro, A. R. (Ed.), Mack Publishing Company, Easton, PA (1985) pp. 1409-1677		
	29	Widder, et al. (ed.), <i>Methods in Enzymology</i> , Vol. 112, Academic Press (1985), pp. 309-396		
EXAMINER		DATE CONSIDERED		